GlassScriptPhysician profile
Iffat Javed Hashmi
NPI 1275391377
$1,757.05
in general payments reported to CMS, 2019-2025
19 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $279 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $261.10 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $260.93 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $234.08 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $196.05 | 2025 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $118.25 | 2024-2025 | Trintellix |
| Actelion Pharmaceuticals US, INC. | $105.72 | 2024-2025 | Uptravi, Opsumit |
| Amneal Pharmaceuticals LLC | $84.76 | 2024-2025 | Unithroid |
| Amgen INC. | $82.98 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $78.09 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $68.25 | 2024-2025 | |
| Abbott Laboratories | $47.32 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.58 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.32 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $29.55 | 2025 | |
| Axsome Therapeutics, INC. | $23.49 | 2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.82 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $20.42 | 2025 | Eliquis |
| Insightec,INC | $20.39 | 2025 | Exablate |
| Phathom Pharmaceuticals, INC. | $18.95 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iffat Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.